Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (1) | Back to Search
Pharmacokinetic characterization of krca-0008 as a novel potent and selective anaplastic lymphoma kinase inhibitor for anticancer treatment
- At: 2017 FIP Congress in Seoul (South Korea)
- Type: Poster
- By: AHN, Sung-Hoon (Kangwon National University, College of Pharmacy, Chuncheon, Korea, Republic Of)
- Co-author(s): Sung-Hoon Ahn: College of Pharmacy, Kangwon National University, Chuncheon, Korea, Republic Of
BackgroundKRCA-0008, bis-ortho-alkoxy-para-piperazinesubstituted-2,4-dianilinopyrimidines, has been under development as a potent and selective Anaplastic lymphoma kinase (ALK) and Ack1 dual inhibitor for anti-cancer treatment. KRCA-0008 has in vivo efficacy with a modest tumor growth inhibition in xenograft mice model bearing H3122 human lung.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019